A real‐world data of Immune checkpoint inhibitors in solid tumors from India

BACKGROUND: Checkpoint inhibitors (Nivolumab and Pembrolizumab) are approved for multiple indications in solid tumors. However access to these therapies is limited in low and middle income countries. Hence we performed an audit to identify accessibility, adverse event rates, compliance, progression...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Noronha, Vanita, Abraham, George, Patil, Vijay, Joshi, Amit, Menon, Nandini, Mahajan, Abhishek, Janu, Amit, Jain, Srushti, Talreja, Vikas T, Kapoor, Akhil, Kumar Singh, Gunjesh, Khaddar, Satvik, Gupta, Kushal, Rathinasamy, Narmadha, Srinivas, Sujay, Agrawal, Amit, Ventrapati, Pradeep, Prabhash, Kumar
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7940210/
https://ncbi.nlm.nih.gov/pubmed/33591635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3617
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados